SEQUENCE LISTING

```
<110> Protherics Molecular Design Limited
<120> CJD Prion testing
<130> 444.39.83372/01
<140> PCT/GB05/000328
<141> 2005-01-27
<150> GB0402123.4
<151> 2004-01-30
<160> 4
<170> PatentIn version 3.0
<210> 1
<211> 29
<212> PRT
<213> synthetic construct
<220>
<221> SITE
<222> (9)..(9)
<223> Xaa is Gly or is absent
<220>
<221> SITE
<222> (10)..(10)
<223> Xaa is Thr or Ser
<220>
<221> SITE
<222> (12)..(12)
<223> Xaa is Gly, Ser or Asn
```

```
<220>
<221> SITE
<222>
        (18)..(18)
<223> Xaa is Asn or Ser
<220>
<221> SITE
<222>
       (23)..(23)
<223> Xaa is Asn or Ser
<220>
<221> SITE
<222> (24)..(24)
<223> Xaa is Met, Leu or Phe
<220>
<221> SITE
<222>
        (27)..(27)
<223> Xaa is Val or Met
<220>
<221> SITE
        (1)..(4)
<222>
        One or more of these residues may be present or absent with the proviso that if they are present they are attached to the rest
<223>
of
        the peptide in sequence
<220>
<221> SITE
<222>
        (26)..(29)
        One or more of these residues may be present or absent with the proviso that if they are present they are attached to the rest
<223>
of
         the peptide in sequence
```

```
Gly Gly Gly Trp Gly Gln Gly Gly Xaa Xaa His Xaa Gln Trp Asn Lys
Pro Xaa Lys Pro Lys Thr Xaa Xaa Lys His Xaa Ala Gly
<210> 2
<211> 24
<212> PRT
<213> synthetic construct
<400> 2
Gly Gln Gly Gly Ser His Ser Gln Trp Asn Lys Pro Ser Lys Pro Lys 1 10 15
Thr Asn Met Lys His Val Gly Cys \overset{20}{}
<210> 3
<211> 31
<212> PRT
<213> synthetic construct
<220>
<221> SITE
<222> (4)..(4)
<223> Xaa is Gly or is absent
<220>
<221> SITE
<222> (29)..(29)
<223> Xaa is Gly or is absent
<220>
<221> SITE
<222> (30)..(30)
<223> Xaa is Gly or Thr
<220>
<221> SITE
<222> (1)..(4)
<223> One or more of these residues may be present or absent with the
```

<400> 1

proviso that if they are present they are attached to the rest of the peptide in sequence $\begin{array}{c} \\ \end{array}$

<220>
<221> SITE
<222> (28)..(31)
<223> One or more of these residues may be present or absent with the proviso that if they are present they are attached to the rest of the peptide in sequence

Pro Gly Gly Xaa Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro Gly Gly Asn Arg Tyr Pro Pro Gln Gly Gly Xaa Xaa Trp
<210> 4
<211> 28
<212> PRT
<213> synthetic construct

<400> 4
Gly Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro
10
Gly Gly Asn Arg Tyr Pro Pro Gln Gly Gly Gly Cys

<400> 3